Cargando…
Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions
The SARS-CoV-2 Virus (COVID-19) is responsible for over 239 million cases and 4.8 million deaths globally (Data source WHO COVID-19 Dashboard accessed on October 14, 2021). It continues to surge and ravage countries, leaving healthcare systems in constant struggle and uncertainty. A variety of vacci...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Medical Association. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613973/ https://www.ncbi.nlm.nih.gov/pubmed/36511275 http://dx.doi.org/10.1016/j.jnma.2022.08.003 |
_version_ | 1784820090122797056 |
---|---|
author | Haq, Hannah N. Khan, Hafiz Chaudhry, Haroon Nimmala, Swathi Demidovich, Joseph Papudesi, Bhavani Nagendra Potluri, Sai Deepika |
author_facet | Haq, Hannah N. Khan, Hafiz Chaudhry, Haroon Nimmala, Swathi Demidovich, Joseph Papudesi, Bhavani Nagendra Potluri, Sai Deepika |
author_sort | Haq, Hannah N. |
collection | PubMed |
description | The SARS-CoV-2 Virus (COVID-19) is responsible for over 239 million cases and 4.8 million deaths globally (Data source WHO COVID-19 Dashboard accessed on October 14, 2021). It continues to surge and ravage countries, leaving healthcare systems in constant struggle and uncertainty. A variety of vaccines were developed to combat the spread of the COVID-19 Virus. Reports of possible allergic reactions with COVID-19 vaccines are a significant cause of public concern, especially among those with a known history of a severe allergic reaction (e.g., anaphylaxis). Here we review articles relevant to COVID-19 vaccines and their excipients (especially PEG (Polyethylene glycol) and hypersensitivity reactions associated with COVID-19 vaccines (including clinical features, pathophysiology, special populations receiving COVID-19 vaccinations, potential diagnostic tests, and preventive measures that can be taken to minimize the risks of hypersensitivity reactions with COVID-19 vaccines). |
format | Online Article Text |
id | pubmed-9613973 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | National Medical Association. Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96139732022-10-28 Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions Haq, Hannah N. Khan, Hafiz Chaudhry, Haroon Nimmala, Swathi Demidovich, Joseph Papudesi, Bhavani Nagendra Potluri, Sai Deepika J Natl Med Assoc Short Review The SARS-CoV-2 Virus (COVID-19) is responsible for over 239 million cases and 4.8 million deaths globally (Data source WHO COVID-19 Dashboard accessed on October 14, 2021). It continues to surge and ravage countries, leaving healthcare systems in constant struggle and uncertainty. A variety of vaccines were developed to combat the spread of the COVID-19 Virus. Reports of possible allergic reactions with COVID-19 vaccines are a significant cause of public concern, especially among those with a known history of a severe allergic reaction (e.g., anaphylaxis). Here we review articles relevant to COVID-19 vaccines and their excipients (especially PEG (Polyethylene glycol) and hypersensitivity reactions associated with COVID-19 vaccines (including clinical features, pathophysiology, special populations receiving COVID-19 vaccinations, potential diagnostic tests, and preventive measures that can be taken to minimize the risks of hypersensitivity reactions with COVID-19 vaccines). National Medical Association. Published by Elsevier Inc. 2022-12 2022-10-28 /pmc/articles/PMC9613973/ /pubmed/36511275 http://dx.doi.org/10.1016/j.jnma.2022.08.003 Text en © 2022 National Medical Association. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Review Haq, Hannah N. Khan, Hafiz Chaudhry, Haroon Nimmala, Swathi Demidovich, Joseph Papudesi, Bhavani Nagendra Potluri, Sai Deepika Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions |
title | Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions |
title_full | Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions |
title_fullStr | Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions |
title_full_unstemmed | Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions |
title_short | Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions |
title_sort | pfizer-biontech (bnt162b2), moderna (mrna-1273) covid-19 mrna vaccines and hypersensitivity reactions |
topic | Short Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613973/ https://www.ncbi.nlm.nih.gov/pubmed/36511275 http://dx.doi.org/10.1016/j.jnma.2022.08.003 |
work_keys_str_mv | AT haqhannahn pfizerbiontechbnt162b2modernamrna1273covid19mrnavaccinesandhypersensitivityreactions AT khanhafiz pfizerbiontechbnt162b2modernamrna1273covid19mrnavaccinesandhypersensitivityreactions AT chaudhryharoon pfizerbiontechbnt162b2modernamrna1273covid19mrnavaccinesandhypersensitivityreactions AT nimmalaswathi pfizerbiontechbnt162b2modernamrna1273covid19mrnavaccinesandhypersensitivityreactions AT demidovichjoseph pfizerbiontechbnt162b2modernamrna1273covid19mrnavaccinesandhypersensitivityreactions AT papudesibhavaninagendra pfizerbiontechbnt162b2modernamrna1273covid19mrnavaccinesandhypersensitivityreactions AT potlurisaideepika pfizerbiontechbnt162b2modernamrna1273covid19mrnavaccinesandhypersensitivityreactions |